Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-14
2008-11-25
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S272100
Reexamination Certificate
active
07456200
ABSTRACT:
The present invention relates to new compounds of formula I,a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing compounds of the formula I and to the use of compounds of the formula I in therapy.
REFERENCES:
patent: 3740434 (1973-06-01), Berkelhammer et al.
patent: 3816426 (1974-06-01), Lee
patent: 5140034 (1992-08-01), Baker et al.
patent: 5631269 (1997-05-01), Broughton et al.
patent: 2005/0272779 (2005-12-01), Edwards et al.
patent: 2007/0129408 (2007-06-01), Minidis et al.
patent: 0 377 457 (1990-07-01), None
patent: 0 397 365 (1990-11-01), None
patent: 0 422 369 (1991-04-01), None
patent: 0 438 230 (1997-04-01), None
patent: 2 070 603 (1981-09-01), None
patent: WO 98/57969 (1998-12-01), None
patent: WO 99/26927 (1999-06-01), None
patent: WO 00/35285 (2000-06-01), None
patent: WO 00/35913 (2000-06-01), None
patent: WO 00/63204 (2000-10-01), None
patent: WO 01/12627 (2001-02-01), None
patent: WO 01/26656 (2001-04-01), None
patent: WO 01/47918 (2001-07-01), None
patent: WO 02/24680 (2002-03-01), None
patent: WO 02/46166 (2002-06-01), None
patent: WO 03/008411 (2003-01-01), None
patent: WO 2005/077345 (2005-08-01), None
patent: WO 2005/080397 (2005-09-01), None
Shishue Chiou et al., “A Simplified Procedure for Preparing 3,5-Disubstituted-1,2,4-Oxadiazoles by Reaction of Amidoximes with Acyl Chlorides in Pyridine Solution”, J. Heterocyclic Chem., 26, (1989), pp. 125-128.
Jong Chan Lee et al., “A Novel and Direct Synthesis of 2-Alkyl-5-Aryl Disubstituted Oxazoles”, Tetrahedron Letters, vol. 38, No. 52, pp. 8959-8960, 1997.
Andrew J. Phillips et al., “Synthesis of Functionalized Oxazolines and Oxazoles with DAST and Deoxo-Fluor”, Org. Lett., vol. 2, No. 8, 2000, pp. 1165-1168.
Stephen T. Meller et al., “Acute Mechanical Hyperalgesia is Produced by Coactivation of AMPA and Metabotropic Glutamate Receptors”, NeuroReport, vol. 4, No. 7, Jul. 1993, pp. 879-882.
Norton P. Peet et al., “Factors Which Influence the Formation of Oxadiazoles from Anthranilhydrazides and Other Benzoylhydrazines”, J. Heterocyclic Chem., vol. 21, 1807-1816 (1984).
Andrius Baskys, “Metabotropic receptors and ‘slow’ excitatory actions of glutamate agonists in the hippocampus”, TINS, vol. 15, No. 3, 1992, pp. 92-96.
Darryle D. Schoepp et al., “Metabotropic glutamate receptors in brain function and pathology”, TIPS, vol. 14, 1993, pp. 13-20.
Darryle D. Schoepp et al., “Novel Functions for Subtypes of Metabotropic Glutamate Receptors”, Neurochem. Int. vol. 24, No. 5, pp. 439-449, 1994.
J.-P. Pin et al., “Review: Neurotransmitter receptors 1 The Metabotropic Glutamate Receptors: Structure and Functions”, Neuropharmacology vol. 34, No. 1, pp. 1-26, 1995.
Shigetada Nakanishi, “Metabotropic Glutamate Receptors: Synaptic Transmission, Modulation, and Plasticity”, Neuron, vol. 13, 1031-1037, Nov. 1994.
Thomas Knöpfel et al., “Metabotropic Glutamate Receptors: Novel Targets for Drug Development”, Journal of Medicinal Chemistry, vol. 38, No. 9, Apr. 1995, pp. 1417-1426.
Jean-Philippe Pin et al., “Alternative splicing generates metabotropic glutamate receptors inducing different patterns of calcium release inXenopus oocytes”, Neurobiology, Proc. Natl. Acad. Sci. USA, vol. 89, pp. 10331-10335, Nov. 1992.
Cécile Joly et al., “Molecular, Functional and Pharmacological Characterization of the Metabotropic Glutamate Receptor Type 5 Splice Variants: Comparison with mGluR1”, The Journal of Neuroscience, May 1995, vol. 15, No. 5, pp. 3970-3981.
“Trends in Pharmacological Sciences including Toxicological Sciences”, Reference Edition, vol. 13, 1992, Elsevier Science Ltd.
“Meeting Reports: Angiosuppressive Therapy for Cancer”, TIPS, vol. 15, Feb. 1994, pp. 33-36.
Zafar I. Bashir et al, “Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors”, Nature, vol. 363, May 1993, pp. 347-350.
Z. A. Bortolotto et al., “A molecular switch activated by metabotropic glutamate receptors regulates induction of long-term potentiation”, Nature. vol. 368, Apr. 1994, pp. 740-743.
Atsu Aiba et al, “Reduced Hippocampal Long-Term Potentiation and Context-Specific Deficit in Associative Learning in mGluR1 Mutant Mice”, Cell, vol. 79, Oct. 1994, pp. 365-375.
Atsu Aiba et al., “Deficient Cerebellar Long-Term Depression and Impaired Motor Learning in mGluR1 Mutant Mice”, Cell, vol. 79, Oct. 1994, 377-388.
Fabio Bordi et al., “Involvement of mGluR5on acute nociceptive transmission”, Brain Research 871 (2000), pp. 223-233.
Michael Hollmann et al., “Cloned Glutamate Receptors” Annu. Rev. Neurosci., 1994, 17, 31-108.
Will P.J.M. Spooren et al., “Novel allosteric antagonists shed light on mglu5receptors and CNS disorders”, TRENDS inj Pharmacological Sciences, vol. 22, No. 7, 2001, pp. 331-337.
Fabrizio Gasparini et al., “Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives”, Neurosciences, 2002, pp. 43-49.
Volker Neugebauer, “Metabotropic glutamate receptors—important modulators of nociception and pain behavior” Pain , 98, 2002, pp. 1-8.
Ichiro Aramori et al., “Signal Transduction and Pharmacological Characteristics of a Metabotropic Glutamate Receptor, mGluR1, in Transfected CHO Cells”, Neuron, vol. 8, Apr. 1992, pp. 757-765.
Yasuto Tanabe et al., “A Family of Metabotropic Glutamate Receptors”, Neuron, vol. 8, 169-179, Jan. 1992.
Stephan Miller et al., “Growth Factor Upregulation of a Phosphoinositide-Coupled Metabotropic Glutamate Receptor in Cortical Astrocytes”, The Journal of Neuroscience, 15(9), Sep. 1995, pp. 6103-6109.
Robert Balåzs et al., “Metabotropic Glutamate Receptor mGluR5 in astrocytes: Pharmacological Properties and Agonist Regulation”, J. Neurochem., vol. 69, No. 1, 1997, pp. 151-163.
M. Schlosser, “Organometallics in Synthesis”, A Manual, Edited by M. Schlosser, Universite de Lausanne, Lausanne, Switzerland, 1994, John Wiley & Sons Ltd., West Sussex England.
Rébecca F. Poulain et al., “Parallel synthesis of 1,2,4-oxadiazoles from carboxylic acids using an improved, uranium-based, activation”, Tetrahedron Letters 42 (2001), pp. 1495-1498.
Anthony R. Gangloff et al., “Synthesis of 3,5-disubstituted-1,2,4-oxadiazoles using tetrabutylammonium fluoride as a mild and efficient catalyst”, Tetrahedron Letters 42 (2001) 1441-1443.
Robert J. Mathvink et al., “Potent, Selective Human β3Adrenergic Receptor Agonists Containing a Substituted Indoline-5-Sulfonamide Pharmacophore”, Bioorganic & Medicinal Chemistry Letters 9 (1999) 1869-1874.
Reiko Minakami et al, “Molecular Cloning and the Functional Expression of Two Isoforms of Human Metabotropic Glutamate Receptor Subtype 5”, Biochemical and Biophysical Research Communications, vol. 199, No. 3, Mar. 1994, pp. 1136-1143.
Jae Nyoung Kim et al., “A Convenient Synthesis of Benzohydroximoyl Chlorides as Nitrile Oxide Precursors by HCI/N,N-Dimethylformamide/Oxone System”, J. Org. Chem. 1992, 57. pp. 6649-6650.
Chun-Sing Li et al., “Synthesis of pyran-4-ones from isoxazoles”, Tetrahedron Letters 43 (2002) 3565-3568.
Branko S. Jursic et al., “Preparation of 5-substituted 2-Methyl-1,3,4-Oxadiazoles from 5-Substituted Tetrazoles and Acetic Anhydride”, Synthetic Communications, 24(11), 1575-1582 (1994).
John Saunders et al., “Novel Quinuclidine—Based Ligands for the Muscarinic Cholinergic Receptor”, J. Med. Chem. 1990, 33, 1128-1138.
Akio Kakefuda et al., “Discovery of 4,5-Diphenyl-1,2,4-triazole Derivatives as a Novel Class of Selective Antagonists for the Human V1
Arora Jalaj
Edwards Louise
Gyback Helena
Isaac Methvin
Johansson Martin
Anderson Rebecca L
Astrazeneca AB
Birch & Stewart Kolasch & Birch, LLP
LandOfFree
Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4041958